Partridge Jeffrey M, Koutsky Laura A
Department of Epidemiology, University of Washington HPV Research Group, University of Washington, Seattle, WA 98103, USA.
Lancet Infect Dis. 2006 Jan;6(1):21-31. doi: 10.1016/S1473-3099(05)70323-6.
Genital human papillomavirus (HPV) infection, globally one of the most common sexually transmitted infections, is associated with cancers, genital warts, and other epithelial lesions. Although a consistent and coherent picture of the epidemiology and pathogenesis of genital HPV infections in women has developed over the past two decades, less is known about these infections in men. Available data suggest that, as with women, most genital HPV infections in men are symptomless and unapparent, and that HPV16 is probably the most frequently detected type. In populations of similar age, the prevalence of specific HPV types is usually lower in men than in women. Whether this observation relates to lower incidence or shorter duration of infection in men than in women has not yet been determined. Seroprevalence of specific anti-HPV antibodies also seems to be lower in men than in women of similar age, a difference that might be due to lower viral load, lower incidence or duration of infection or lower antibody responses, or both, in men compared with women. Differences in sexual behaviour may also be important predictors of genital HPV infection. With the anticipated availability of prophylactic HPV vaccines in the near future, it becomes increasingly important to understand the incidence and duration of HPV infections in men to develop cost-effective approaches to prevention through a combination of immunisation and promotion of risk-reduction strategies.
生殖器人乳头瘤病毒(HPV)感染是全球最常见的性传播感染之一,与癌症、尖锐湿疣及其他上皮病变相关。尽管在过去二十年里,关于女性生殖器HPV感染的流行病学和发病机制已形成了连贯一致的认识,但对于男性的此类感染却知之甚少。现有数据表明,与女性一样,男性的大多数生殖器HPV感染没有症状且不易察觉,HPV16可能是最常检测到的类型。在年龄相仿的人群中,特定HPV类型在男性中的流行率通常低于女性。这种现象是与男性感染发生率较低还是感染持续时间较短有关,目前尚未确定。特定抗HPV抗体的血清流行率在男性中似乎也低于年龄相仿的女性,这种差异可能是由于男性的病毒载量较低、感染发生率或持续时间较短,或者抗体反应较低,或两者兼而有之。性行为差异也可能是生殖器HPV感染的重要预测因素。随着预防性HPV疫苗有望在不久的将来问世,了解男性HPV感染的发生率和持续时间,以便通过免疫接种和推广降低风险策略相结合的方式制定具有成本效益的预防方法,变得越来越重要。